drugset / Trial / NCT05428826

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

NCT05428826

Phase 4 Recruiting 41 enrolled Assistance Publique - Hôpitaux de Paris
NaSingle-groupOpen-labelTreatment

Summary

Adult patients with a diagnosis of idiopathic retroperitoneal fibrosis Prospective multicentric cohort study Intervention : administration of prednisone during 9 to 21 months at 1mg/kg/day at inclusion.

Timeline

Start
2022-11-25
Primary completion
2026-11-25
Completion
2028-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified 1 mg/kg Oral

Indications

No indication recorded.